Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update

RTTNews | 467 दिनों पहले
Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update

(RTTNews) - While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) reaffirmed its adjusted earnings guidance for the full-year 2023.

For fiscal 2023, the company now projects earnings in a range of $3.02 to $3.22 per share and adjusted earnings in a range of $4.30 to $4.50 per share.

Previously, the company expected earnings in the range of $3.05 to $3.25 per share and adjusted earnings in the range of $4.30 to $4.50 per share.

On average, 24 analysts polled by Thomson Reuters expect the company to report earnings of $4.40 per share for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

टैग: ABT
read more
Abbott Laboratories Boosts FY24 Earnings Outlook - Update

Abbott Laboratories Boosts FY24 Earnings Outlook - Update

While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) provided earnings and adjusted earnings guidance for the third quarter and raised its outlook for the full-year 2024.
RTTNews | 103 दिनों पहले
Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor

Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor

Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
RTTNews | 530 दिनों पहले
Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain

Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain

Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
RTTNews | 532 दिनों पहले
Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN

Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN

Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.
RTTNews | 642 दिनों पहले